13 names are moving together; 46% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | Healthcare | -6.0% | Most structurally connected |
| RCUS | Arcus Biosciences, Inc. | Healthcare | +0.1% | Group member |
| RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | -6.1% | Group member |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | -5.2% | Group member |
| RVMD | Revolution Medicines, Inc. | Healthcare | -2.3% | Group member |
| PRAX | Praxis Precision Medicines, Inc | Healthcare | -0.2% | Group member |
| IRON | Disc Medicine, Inc. | Healthcare | -2.8% | Group member |
| CGON | CG Oncology, Inc. | Healthcare | -2.6% | Group member |
| ACA | Arcosa, Inc. | Industrials | +0.1% | Group member |
| MANE | Veradermics, Incorporated | Healthcare | -0.1% | Group member |
| TYRA | Tyra Biosciences, Inc. | Healthcare | -3.5% | Group member |
| CELC | Celcuity Inc. | Healthcare | -1.4% | Group member |
| APGE | Apogee Therapeutics, Inc. | Healthcare | -0.1% | Group member |
Cohort
13 namesParticipation
46% this sessionObserved history
1 daily buildsFiling coverage
13/13 membersproduct pipeline / R&D affecting expense
“The increase in general and administrative expenses was primarily due to higher personnel and related costs associated with the build-out of our commercial organization and other supporting functions in preparation for our planned commercial launch..”
COGT 10-Q
demand / volume
“We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers.”
COGT 10-K
credit / rates affecting interest expense
“As a result of this amortization, the interest expense that we expect to recognize for the Notes for accounting purposes will be greater than the cash interest payments we will pay on the Notes, which will result in lower reported income.”
COGT 10-K
Clinical-Stage Biotech can stay leader-led if RVMD and the next software names fail to join while COGT keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.